Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Rhea-AI Summary

BASKING RIDGE, N.J., March 3, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) announces its participation in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The company will present an overview and hold virtual investor meetings. Investors can register via the provided link. Caladrius focuses on developing cellular therapies aimed at reversing diseases, with products like CLBS16 and HONEDRA® currently in clinical trials. For more information, visit www.caladrius.com.

BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

If you are an institutional investor, and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/globalconference ) to register for the conference. Over 400 corporate presentations & panels are available Live and on-demand during March 9-10, 2021, starting on March 9 at 7:00 A.M. (EST).

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”) and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the U.S. Food and Drug Administration (the “FDA”) to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).  For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: jmenditto@caladrius.com

FAQ

When is Caladrius Biosciences presenting at the H.C. Wainwright Global Life Sciences Virtual Conference?

Caladrius Biosciences will present at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021.

What is the focus of Caladrius Biosciences?

Caladrius Biosciences focuses on developing cellular therapies intended to reverse various diseases.

What products are currently under development by Caladrius?

Caladrius is developing several products, including CLBS16, HONEDRA® (CLBS12), and CLBS201, targeting conditions like coronary microvascular dysfunction and chronic kidney disease.

How can investors register for the Caladrius presentation?

Investors can register for the presentation by clicking on the link provided in the press release.

What is the stock symbol for Caladrius Biosciences?

The stock symbol for Caladrius Biosciences is CLBS.